

WEST[Generate Collection](#)[Print](#)**Search Results - Record(s) 1 through 1 of 1 returned.**☐ 1. Document ID: WO 9918206 A2 AU 9895720 A EP 1021535 A2

L3: Entry 1 of 1

File: DWPI

Apr 15, 1999

DERWENT-ACC-NO: 1999-277270

DERWENT-WEEK: 199923

COPYRIGHT 2003 DERWENT INFORMATION LTD

TITLE: Cancer antigen NY ESO1/CAG-3

INVENTOR: ROSENBERG, S A; WANG, R F

PATENT-ASSIGNEE:

ASSIGNEE

US DEPT HEALTH & HUMAN SERVICES

CODE

USSH

PRIORITY-DATA: 1997US-061428P (October 8, 1997)

PATENT-FAMILY:

PUB-NO	PUB-DATE	LANGUAGE	PAGES	MAIN-IPC
WO 9918206 A2	April 15, 1999	E	087	C12N015/12
AU 9895720 A	April 27, 1999		000	
EP 1021535 A2	July 26, 2000	E	000	C12N015/12

DESIGNATED-STATES: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI
GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW
MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW AT BE CH
CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC MW NL OA PT SD SE SZ UG ZW AT
BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

APPLICATION-DATA:

PUB-NO	APPL-DATE	APPL-NO	DESCRIPTOR
WO 9918206A2	September 21, 1998	<u>1998WO-US19609</u>	
AU 9895720A	September 21, 1998	1998AU-0095720	
AU 9895720A		WO 9918206	Based on
EP 1021535A2	September 21, 1998	1998EP-0949385	
EP 1021535A2	September 21, 1998	<u>1998WO-US19609</u>	
EP 1021535A2		WO 9918206	Based on

INT-CL (IPC): A01 K 67/027; A61 K 35/14; A61 K 38/08; A61 K 38/10; A61 K 38/17; C07 K 14/47; C07 K 16/18; C12 N 5/08; C12 N 15/11; C12 N 15/12; C12 N 15/86; C12 Q 1/68

ABSTRACTED-PUB-NO: WO 9918206A

BASIC-ABSTRACT:

NOVELTY - Cancer peptide (I), designated NY ESO-1/CAG-3, and its functional fragments and derivatives, encoded by a nucleic acid sequence (Ii) of 906 bp (reproduced) or its variants.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for the following:

- (a) cancer peptides and analogs of formula (Ia);
- (b) pharmaceutical composition containing (I) or (Ia) and a carrier;
- (c) immunogen comprising at least one (I) or (Ia) and optionally an immunostimulant;
- (d) nucleic acid (II) comprising sequence (Ii), its fragments or homologs;
- (e) recombinant expression vector containing (II);
- (f) host organisms transformed or transfected with this vector;
- (g) oligonucleotides (ON) complementary to (II);
- (h) recombinant virus including (II) in its genome;
- (i) host organism transformed or transfected with this virus;
- (j) antibody, or its antigen-binding fragments, that bind to (I);
- (k) recombinant production of (I);
- (l) detecting (pre)cancer by measuring an increased level of (Ii)-derived mRNA;
- (m) detecting (I)-encoding genomic nucleic acid by hybridization with a (Ii)-derived probe;
- (n) detection of (I) by immunoassay;
- (o) prevention or inhibition of cancer using (I) or the virus of (h);
- (p) pharmaceutical composition containing the virus of (h);
- (q) transgenic animals expressing a gene encoding (I);
- (r) human cytotoxic T lymphocytes (CTL) specific for (I).

X1 = absent or 1-10 amino acids;

X2 = A, T, V, L or R;

X3 = S or a conservative substitution;

X4 = R or K

ACTIVITY - Anticancer.

MECHANISM OF ACTION - (I) is recognized by T cells as an antigen so stimulates a specific immune response. The peptide ASGPGGGAPR was introduced into HLA-A31-positive 1510EBV B cells, then assessed for ability to stimulate cytokine release from a T cell clone that recognized (I). The peptide stimulated release of granulocyte-macrophage colony-stimulating factor at over 2000 pg/ml.

USE - Nucleic acid (II) encoding (I) is used to detect (pre)cancer, particularly melanoma or breast cancer, by detecting increased levels of (I)-related mRNA, also to detect corresponding genomic nucleic acid by hybridization. Oligonucleotides from (II) are used as probes and primers and as antisense inhibitors of (I) expression. Transgenic animals containing (II) are used to screen for potential anticancer agents. (I), optionally combined with an HLA (human leucocyte antigen) molecule, are used (i) in vaccines to prevent or inhibit cancer or (ii) to induce, in vitro, cancer-specific T cells for subsequent return to a patient for treating melanoma. Recombinant viruses containing (II) are used similarly.

CHOSEN-DRAWING: Dwg.0/7

TITLE-TERMS: CANCER ANTIGEN

DERWENT-CLASS: B04 D16 P14

CPI-CODES: B04-C01G; B04-E03F; B04-E08; B04-F0100E; B04-G01; B04-N02A; B04-P0100E; B12-K04A1; B12-K04E; B14-H01; B14-S11C; D05-H07; D05-H09; D05-H12A; D05-H12E; D05-H14; D05-H17A6;

CHEMICAL-CODES:

Chemical Indexing M1 *01*
Fragmentation Code
M423 M710 M905 P831 Q233
Specific Compounds
A00NSN

Chemical Indexing M1 *02*
Fragmentation Code
M423 M710 M905 P831 Q233
Specific Compounds
A00GTN

Chemical Indexing M1 *03*
Fragmentation Code
M423 M710 M905 P831 Q233
Specific Compounds
A013IN

Chemical Indexing M1 *04*
Fragmentation Code
M423 M710 M905 P633 Q233
Specific Compounds
A00H1T A00H1N

Chemical Indexing M1 *05*
Fragmentation Code
M423 M710 M905 P633 Q233
Specific Compounds
A00GTT A00GTN

Chemical Indexing M1 *06*
Fragmentation Code
M423 M750 M905 N102 P831 Q233
Specific Compounds
A012PK A012PA

Chemical Indexing M1 *07*
Fragmentation Code
M423 M750 M905 N102 P831 Q233
Specific Compounds
A00NSK A00NSA

SECONDARY-ACC-NO:

CPI Secondary Accession Numbers: C1999-081449

Non-CPI Secondary Accession Numbers: N1999-207830

Full	Title	GIT.1	REV.1	GLS.1	REF.1	SEQ.1	ATT.1
RAW.1	CP.1						

[Generate Collection](#)[Print](#)

Terms	Documents
1998wo-us19609.ap,prai.	1

Display Format: [FULL](#) [Change Format](#)[Previous Page](#)[Next Page](#)